Sex-specific mortality prediction by pro-C-type natriuretic peptide measurement in a prospective cohort of patients with ST-elevation myocardial infarction.
ANP
C-type natriuretic peptide
CNP
myocardial infarction
natriuretic peptides
reference intervals
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
28 09 2021
28 09 2021
Historique:
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
To determine the predictive value of pro-C-type natriuretic peptide (pro-CNP) measurement in plasma sampled on admission from patients presenting with ST-elevation myocardial infarction (STEMI). Prospective cohort study. Two University Hospitals in Denmark. 1760 consecutive patients (470 females and 1290 males) with confirmed STEMI. The main outcome was all-cause mortality at 1 year after presentation and the primary measure was pro-CNP concentration in plasma at admission in all patients and longitudinal measurements in a consecutive subgroup of 287 patients. A reference population (n=688) defined cut-off values of increased pro-CNP concentrations. In all patients, an increased pro-CNP concentration was associated with a higher all-cause mortality after 1 year (HR 1.6, 95% CI 1.1 to 2.4, P In female but not male patients presenting with STEMI, high concentrations of pro-CNP (≥median) at admission independently indicate a higher risk of all-cause mortality. The findings are remarkably specific for female patients, suggesting a different vascular phenotype beyond traditional measures of coronary artery flow compared with male patients.
Identifiants
pubmed: 34588247
pii: bmjopen-2020-048312
doi: 10.1136/bmjopen-2020-048312
pmc: PMC8480007
doi:
Substances chimiques
Biomarkers
0
Natriuretic Peptide, Brain
114471-18-0
Natriuretic Peptide, C-Type
127869-51-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e048312Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Curr Mol Med. 2003 Feb;3(1):25-38
pubmed: 12558072
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
Clin Chem. 2017 Jan;63(1):316-324
pubmed: 28062626
Scand J Clin Lab Invest. 2004;64(4):327-42
pubmed: 15223699
Clin Endocrinol (Oxf). 2013 May;78(5):783-9
pubmed: 22963390
Clin Chem Lab Med. 2017 Nov 27;56(1):132-137
pubmed: 28688223
Nat Rev Cardiol. 2009 Aug;6(8):532-42
pubmed: 19564884
Clin Chem Lab Med. 2004;42(7):710-4
pubmed: 15327004
J Immunol Methods. 2010 Oct 31;362(1-2):32-7
pubmed: 20797397
Circulation. 2019 Mar 26;139(13):1612-1628
pubmed: 30586761
Hypertension. 2017 Feb;69(2):286-296
pubmed: 28049696
Circulation. 2018 Jul 31;138(5):494-508
pubmed: 29626067
Eur Heart J. 2020 Mar 1;41(9):1006-1020
pubmed: 30903134
Eur J Heart Fail. 2014 Sep;16(9):958-66
pubmed: 25082741
Hypertension. 2009 Sep;54(3):612-8
pubmed: 19620509
J Endocrinol. 2008 Dec;199(3):481-7
pubmed: 18784186
Biochem Biophys Res Commun. 2014 Jul 4;449(3):301-6
pubmed: 24845564
Hypertension. 1997 Jun;29(6):1296-302
pubmed: 9180632
Eur Heart J Acute Cardiovasc Care. 2018 Feb;7(1):7-15
pubmed: 28452562
J Clin Invest. 2006 Jan;116(1):49-58
pubmed: 16341264
Nat Rev Cardiol. 2020 Nov;17(11):698-717
pubmed: 32444692
Hypertension. 2015 Jun;65(6):1187-94
pubmed: 25895587
Atherosclerosis. 2015 Jul;241(1):205-7
pubmed: 26003338
Peptides. 2011 Sep;32(9):1964-71
pubmed: 21816187
Am J Physiol. 1992 Oct;263(4 Pt 2):H1318-21
pubmed: 1384363
J Cardiovasc Pharmacol. 1998 Jul;32(1):5-11
pubmed: 9676714
Ann Biomed Eng. 1999 Jul-Aug;27(4):419-26
pubmed: 10468226
Science. 2005 Jun 10;308(5728):1583-7
pubmed: 15947175
J Immunol Methods. 2011 Jul 29;370(1-2):104-10
pubmed: 21703274